**ABO478**

**CORONARY ATHEROSCLEROSIS IN BEHCET’S DISEASE**

R. Goloeva1, Z. Alekberova, V.A. Nasonova Research Institute of Rheumatology, Moscow, Russian Federation

**Background:** Behçet’s disease (BD) is systemic vasculitis, which affects all types and sizes of vessels. Increased carotid intima-media thickness (IMT) is parameter associated with subclinical atherosclerosis.

**Objectives:** To determine the prevalence of atherosclerosis in pts with BD.

**Methods:** 95 BD pts were evaluated and 45 healthy controls matched for age and gender. IMT was assessed by high-resolution B-mode ultrasonography. Serum concentration of high-sensitive C-reactive protein (hs CRP) was measured by immunonephelometric assay (BN-100 Analyzer; Dade Behring). Lipid profile evaluation included total cholesterol, TGs, HDL, LDL, and atherogenic index.

**Results:** The male-to-female ratio was 3:7:1, the mean age of pts was 29.7 (23-35) yrs, the mean age at the disease onset - 19.9 (14-25) yrs, the mean disease duration - 9.6 (4-15) yrs.

**Conclusion:** Deseasional function was found in patients with high SLE activity treated with CP with Rituximab.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2020-eular.3465

**ABO480**

**AN OPEN-LABEL, EXPLORATORY STUDY TO ESTABLISH THE EFFICACY AND SAFETY OF 1-YEAR CANAKINUMAB TREATMENT IN BEHCET’S DISEASE PATIENTS WITH NEUROLOGIC OR VASCULAR INVOLVEMENT**

A. Güll1, M. Kurtuncu1, M. Erdugan1, E. Oguz2, T. Gunduz2, G. Akman Demir1, S. Sevq1,2, S. Turgay1, E. Acar1, 2Istanbul Faculty of Medicine, Istanbul, Turkey; 2Istanbul Faculty of Medicine, Istanbul, Turkey; 3Novartis Turkey, Istanbul, Turkey; 4Novartis Turkey, Istanbul, Turkey; 5Novartis Turkey, Istanbul, Turkey

**Background:** Previous observations in Behcet's disease (BD) patients receiving anti-IL-1 therapies suggested that dosage and route of administration may be critical in controlling disease manifestations. This was supported by favorable observations with infliximab infusions reaching higher serum trough levels in refractory BD patients compared to other anti-TNF agents.

**Objectives:** The primary objective was to evaluate the safety and efficacy of intravenous (IV) canakinumab (CAN) on the clinical and inflammatory findings of BD patients with neurologic and vascular involvement.

**Methods:** Biologic-naive BD patients, who had a recent attack of large vessel vascular or parenchymal neurologic disease within the last month were enrolled and all received 300 mg CAN IV without a change in other medications. Response was assessed on day 30 as the primary objective; partial
responders were able to take the 2nd 300 mg IV on day 30 and continued the treatment with monthly 150 mg IV 4 times. Others continued the treatment with 150 mg IV monthly. At month 6, patients were able to switch to SC injections or continue 150 mg IV for 6 months. Non-responder patients were dropped out. Prednisolone dosage was ≤20 mg at baseline and not increased during the trial. Complete response was defined as full clinical recovery to pre-attack state, disappearance of MRI lesions, normalization of CSF findings; partial response was defined as partial improvement in clinical findings, which were still worse than pre-attack state, with MRI lesions becoming smaller with no or less enhancement, and a decrease in CSF cell count. Complete response of vascular findings was defined as ≥50% improvement in patient’s and physician’s global assessments, ≥50% reduction in CRP; along with stable or ≥20% reduced aneurysm size or stable or ≥20% reduced calf swelling; and partial response was an improvement between 20-49% in global assessments, 20-49% reduction in CRP; stable or ≤20% reduced aneurysm size or ≤20% reduced calf swelling.

Results: 9 subjects were screened, and 8 male subjects (5 vascular, 3 neurological) aged 27.3 ± 2.3 years entered the study. No new attack or worsening of manifestations was observed, and at least a partial response was obtained in all patients on day 30. Two vascular patients (2/5, 40%) and 1 neurological patient (1/3, 33%) received another 300 mg infusion on day 30; one of them left the study on day 120 because of safety concerns after noticing the use of illicit drugs, and the other required 150 mg IV CAN after day 180 and discontinued the study because of the worsening of pulmonary artery aneurysm, despite favorable response in venous findings. The remaining 3 patients (3/6, 50%) with deep vein thrombosis completed the study with clinical and radiological improvement. 2 patients with parenchymal involvement had lesions in the brain stem and showed complete improvement of clinical findings between 1-3 months and radiologic findings between 3-6 months. Clinical findings of 1 patient with sinus thrombosis improved within 2 months, and the last cranial MRI showed that the vein thrombus was recanalized. Patients experienced other mild manifestations of BD following a switch to SC administration.

Conclusion: Response to CAN without high-dose methylprednisolone treatment suggests that IL-1 antagonism plays a role in acute exacerbations of neurologic and vascular manifestations of BD, and no new safety signal was recorded with IV use. Favorable responses during the early months of the study and development of clinical and laboratory findings after switching to SC administration may suggest that achievement of higher serum trough levels may be critical, and up-titration of the dosages may provide better results in individual patients with high inflammatory activity.

References: NA

Acknowledgments: This study was supported by Novartis.

Disclosure of Interests: Ahmet Güle: None declared, Murat Kurtuncu Grant/ research support from: Travel, symposia speaker and Honoraria grants (Novartis, Bayer, Teva, Ali Raif, Gen), Consultant of: Novartis, Bayer, Teva, Ali Raif, Gen.

Speakers bureau: (Novartis, Bayer, Teva, Ali Raif, Gen), Murat Erdugan: None declared.

Emin Öngür: None declared.

Tuncay Gunduz: None declared, Ghislen Akman Demir Grant/research support from: Novartis, Serhan Sevgi Grant/research support from: Travel, symposia speaker and Honoraria grants (Novartis, Bayer, Teva, Ali Raif, Gen).

Akrım: None declared.

Serhan Sevgi Employee of: Novartis, Soner Turgay Employee of: Novartis, Ersen Acar Employee of: Novartis

DOI: 10.1136/annrheumdis-2020-eular.4247

AB0481

EFFICACY OF APREMLISAST FOR THE TREATMENT OF GENITAL ULCERS ASSOCIATED WITH ACTIVE BEHÇET’S SYNDROME: A COMBINED ANALYSIS OF TWO RANDOMIZED CONTROLLED TRIALS

G. Hadem1; A. Mahn2; M. Takeno3; D. Kim4; M. Melikoglu5; S. Cheng6; S. Mccue7; S. Richter8; M. Brunoni9; M. Paris10; M. Chen11; Y. Yasu11; Istanbul University Cerrahpaşa, Cerrahpaşa Medical School and Behçet’s Disease Research Center, Istanbul, Turkey; 2Cantonal Hospital St. Gallen, St. Gallen, Switzerland; 3Nippon Medical School, Graduate School of Medicine, Tokyo, Japan; 4Yonsei University College of Medicine and Severance Hospital, Seoul, Korea, Rep. of (South Korea); 5Amgen Inc., Thousand Oaks, United States of America; 6New York University School of Medicine, New York, United States of America

Background: Behçet’s syndrome is a chronic, multi-system inflammatory disorder characterized by painful, recurrent oral ulcers (OU) and genital ulcers (GU). The GU associated with Behçet’s syndrome can contribute to difficulties with sexual activity, walking, and sitting2; may cause scarring1; and may impair quality of life.3,4 Apremlisast (APR), an oral phosphodiesterase 4 inhibitor, has demonstrated efficacy in the treatment of the OU associated with Behçet’s syndrome in the phase III, randomized RELIEF study (BCT-002).

Objectives: To describe the efficacy of APR for the treatment of GU associated with active Behçet’s syndrome in the RELIEF study and in a pooled data analysis of RELIEF and the phase II study.

Methods: Adult patients (≥18 years of age) with active Behçet’s syndrome and ≥3 OU at randomization or ≥2 OU at screening and randomization, without active major organ involvement, were randomized (1:1) to APR 30 mg twice daily or placebo (PBO). In RELIEF, clinical improvement in GU was assessed by evaluating the time to the first GU recurrence after loss of complete response, the total number of GU in patients without GU at baseline, and the proportion of patients who were GU-free (complete response) at Week 12 (regardless of baseline GU status). A pooled analysis of patients in RELIEF and a randomized, phase II study4 were conducted to assess achievement of GU complete response in patients with GU at baseline. In patients with GU complete response before Week 12, the median time to the first GU recurrence after loss of complete response was based on Kaplan-Meier estimates. The mean number of GU was summarized descriptively using data as observed. Between-group differences in the proportion of patients who were GU-free at Week 12 were analyzed by Cochran-Mantel-Haenszel test using non-responder imputation to handle missing data. Statistical tests were 2 sided (α=0.05).

Results: A total of 207 patients were randomized and received ≥1 dose of study medication (APR: n=104; PBO: n=103). In all, 17 patients in the APR group and 17 in the PBO group had GU at baseline, with mean GU counts of 2.9 (APR) and 2.6 (PBO). Among patients with GU at baseline in RELIEF, 12/17 (70.6% [APR]) and 7/17 (41.2% [PBO]) achieved GU complete response at Week 12 (P=0.110). The median time to first GU recurrence in these patients occurred earlier with PBO (6.1 weeks) vs. APR (not calculable). In the pooled analysis of RELIEF and the phase II study, a significantly greater proportion of patients with GU at baseline achieved GU complete response at Week 12 with APR vs. PBO (21/27 [77.8%] vs. 9/23 [39.1%; P=0.011]) (Figure 1). The proportion of patients who were GU-free was significantly greater with APR (92/104 [88.5%]) vs. PBO (72/101 [71.3%]), regardless of baseline number of GU (P=0.002) (Figure 2).

Conclusion: The number of patients with GU was low, but the totality of the data shows a favorable trend in the treatment effect of APR on GU. Greater proportions of APR-treated patients were GU-free at Week 12 vs. patients receiving PBO, and the time to the first GU recurrence occurred earlier with PBO vs. APR.

References:


Figure 1. Complete Response of GU at Week 12 in Patients With GU at Baseline (Pooled RELIEF and Phase II Study Data)

Figure 2. Complete Response of GU at Week 12 in Patients Regardless of the Number of GU at Baseline